Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Because of rarity, role of chemotherapy of bladder adenocarcinoma are still unidentified. Therefore, we performed a retrospective analysis of the clinical features and chemotherapy outcomes of bladder adenocarcinoma. Methods: Eligible patients for this retrospective analysis were initially diagnosed with bladder adenocarcinoma and presented with a clinically no other primary site of origin. The collected data included age, gender, performance status, stage, hemoglobin, albumin, initial date of diagnosis, treatment modality utilized, response to treatment, presence of relapse, last status of patient, and last date of follow-up. Results: We retrospectively reviewed 29 patients, who were treated with chemotherapy for bladder adenocarcinoma at 10 Korean medical institutions from 2004 to 2014. The median age of patients was 58 years (range, 17 to 78) and 51.7% of the patients were female. Urachal adenocarcinoma was identified in 15 patients. Of 27 symptomatic patients, 22 experienced gross hematuria. Twelve patients were treated with 5-f luorouracil based chemotherapy, five were gemcitabine based, three were taxane and others. Thirteen of them achieved complete response (10.3%) or partial response (34.5%). Median progression-free survival (PFS) and overall survival (OS) for all patients were 10.6 months (95% confidence interval [CI], 9.5 to 11.6) and 24.5 months (95% CI, 1.2 to 47.8), respectively. The cases of urachal adenocarcinoma exhibited worse tendency in PFS and OS (p = 0.024 and p = 0.046, respectively). Conclusions: Even though bladder adenocarcinoma had been observed moderate effectiveness to chemotherapy, bladder adenocarcinoma is a highly aggressive form of bladder cancer. PFS and OS were short especially in urachal carcinoma.
Abstract
Background/Aims: Because of rarity, role of chemotherapy of bladder adenocarcinoma are still unidentified. Therefore, we performed a retrospective analysis of the clinical features and chemotherapy outcomes of bladder adenocarcinoma. Methods: Eligible patients for this retrospective analysis were initially diagnosed with bladder adenocarcinoma and presented with a clinically no other primary site of origin. The collected data included age, gender, performance status, stage, hemoglobin, albumin, initial date of diagnosis, treatment modality utilized, response to treatment, presence of relapse, last status of patient, and last date of follow-up. Results: We retrospectively reviewed 29 patients, who were treated with chemotherapy for bladder adenocarcinoma at 10 Korean medical institutions from 2004 to 2014. The median age of patients was 58 years (range, 17 to 78) and 51.7% of the patients were female. Urachal adenocarcinoma was identified in 15 patients. Of 27 symptomatic patients, 22 experienced gross hematuria. Twelve patients were treated with 5-f luorouracil based chemotherapy, five were gemcitabine based, three were taxane and others. Thirteen of them achieved complete response (10.3%) or partial response (34.5%). Median progression-free survival (PFS) and overall survival (OS) for all patients were 10.6 months (95% confidence interval [CI], 9.5 to 11.6) and 24.5 months (95% CI, 1.2 to 47.8), respectively. The cases of urachal adenocarcinoma exhibited worse tendency in PFS and OS (p = 0.024 and p = 0.046, respectively). Conclusions: Even though bladder adenocarcinoma had been observed moderate effectiveness to chemotherapy, bladder adenocarcinoma is a highly aggressive form of bladder cancer. PFS and OS were short especially in urachal carcinoma.
참고문헌 (22)
- Zhong M, "Primary adenocarcinoma of the urinary bladder: differential diagnosis and clinical relevance", Arch Pathol Lab Med, 137, pp.371~381 (2013)[DOI]
- Bates AW, "Secondary neoplasms of the bladder are histological mimics of nontransitional cell primary tumours: clinicopathological and histological features of 282 cases", Histopathology, 36, pp.32~40 (2000)[DOI]
- Bardales RH, "Urine cytology of primary and secondary urinary bladder adenocarcinoma", Cancer, 84, pp.335~343 (1998)[DOI]
- Hong JY, "Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract", Med Oncol, 26, pp.186~192 (2009)[DOI]
- Zhang J, "Options for diagnosis and treatment of urachal carcinoma", Asia Pac J Clin Oncol, 9, pp.117~122 (2013)[DOI]
- Akamatsu S, "Primary signet- ring cell carcinoma of the urinary bladder", Urology, 75, pp.615~618 (2010)[DOI]
- Romics I, "Signet-ring cell carcinoma arising from the urinary bladder", Can J Urol, 15, pp.4266~4268 (2008)
- Smith AK, "Role of cystitis cystica et glandularis and intestinal metaplasia in development of bladder carcinoma", Urology, 71, pp.915~918 (2008)[DOI]
- Zhang H, "Primary adenocarcinoma of the urinary bladder: a single site analysis of 21 cases", Int Urol Nephrol, 45, pp.107~111 (2013)[DOI]
- Dahm P, "Malignant non-urothelial neoplasms of the urinary bladder: a review", Eur Urol, 44, pp.672~681 (2003)[DOI]
- Manunta A, "Non-transitional cell bladder carcinomas", BJU Int, 95, pp.497~502 (2005)[DOI]
- Galsky MD, "Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract", Urology, 69, pp.255~259 (2007)[DOI]
- Siefker-Radtke A, "Urachal adenocarcinoma: a clinician’s guide for treatment", Semin Oncol, 39, pp.619~624 (2012)[DOI]
- Miyata Y, "Response of recurrent urachal cancer to gemcitabine and cisplatin therapy: a case report and literature review", Anticancer Res, 31, pp.2335~2338 (2011)
- Logothetis CJ, "A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors", J Clin Oncol, 8, pp.1050~1055 (1990)[DOI]
- Bellmunt J, "Randomized phase III study comparing paclitaxel", cisplatin, cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987, pp.J Clin Oncol, 2012[DOI]
- De Santis M, "Randomized phase II", III trial assessing gemcitabine, carboplatin, pp.vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986, J Clin Oncol[DOI]
- Ismaili N, "Chemotherapy in advanced bladder cancer: current status and future", J Hematol Oncol, 4, pp.35~ (2011)[DOI]
- Carballido EM, "Optimal treatment for metastatic bladder cancer", Curr Oncol Rep, 16, pp.404~ (2014)[DOI]
- Wright JL, "Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder", Cancer, 107, pp.721~728 (2006)[DOI]
- Mostofi FK, "Mucous adenocarcinoma of the urinary bladder", Cancer, 8, pp.741~758 (1955)[DOI]
- Dandekar NP, "Adenocarcinoma of bladder", Eur J Surg Oncol, 23, pp.157~160 (1997)[DOI]